Associated Papers
Malignant adenomyoepithelioma with HRAS G13R mutation: A case report.
Kuwabara H et al.
Oncology Letters, 2026
IsoPS-DIA: Dual Functionality of Absolute Targeted Quantification and Global Proteome Profiling.
Chan HJ et al.
Analytical Chemistry, 2026
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.
Hu Z et al.
Jacs Au, 2026
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
Clinical relevance of mosaic variants detected by exome sequencing.
Ghosh R et al.
The Journal of Allergy and Clinical Immunology, 2026
Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.
van Tienen LM et al.
Cell Chemical Biology, 2026
Mosaic variants in KRAS and STAT5B associated with a mixed phenotype of 2 acquired errors of immunity.
Forkgen J et al.
The Journal of Allergy and Clinical Immunology, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Precision oncology in Bulgaria: a prospective study of metastatic colorectal cancer patients.
Dimitrov G et al.
Cancer Treatment and Research Communications, 2026
TGFB-inducible VASN (vasorin) promotes lysosomal acidification.
Yan J et al.
Autophagy, 2026
Application of Targeted RNA-Sequencing in High-Risk B-Cell Acute Lymphoblastic Leukemia (B-ALL): Identifying Fusions, IKZF1 Deletions, and CRLF2 Expression in an Indian Cohort.
Gupta SK et al.
International Journal of Laboratory Hematology, 2026
Whole Genome and Single-Cell RNA Sequencing Reveals Clonal Evolution and Heterogeneity of Secondary Plasma Cell Leukemia: A Case Report.
Suzuki T et al.
Ejhaem, 2026
Synonymous Variants of Potential Significance Identified by a 52-Gene Clinical Sequencing Panel in Non-Small Cell Lung Cancer.
Varty K et al.
Genes, Chromosomes & Cancer, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non-small cell lung cancer (NSCLC).
Du Y et al.
Science Advances, 2026
Genomic evolution of pancreatic cancer at single-cell resolution.
Zhang H et al.
Nature Genetics, 2026
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ.
Zhuang WT et al.
The Journal of Clinical Investigation, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.
Lee H et al.
Nature Medicine, 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy.
Htoo A et al.
Journal of the American Society of Cytopathology, 2026
Six-Color Multiplex Digital PCR Assays for Comprehensive Screening and Identification of Multiple Driver Mutations Associated with Pancreatic Carcinogenesis.
Maeda C et al.
Clinical Chemistry, 2026
RAS-variant allele frequency as a potential prognostic marker of overall survival in patients with metastatic colorectal cancer.
Nindra U et al.
Cancer Treatment and Research Communications, 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026
KRAS mutation and its association with clinicopathological features of colorectal cancer patients in Africa: a systematic review and meta-analysis.
Kassaw AB et al.
Bmc Cancer, 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
Baars B et al.
Molecular Cancer Research : Mcr, 2026
Molecular Mosaics: Unveiling Heterogeneity in Synchronous Colorectal Cancers.
Lee HG et al.
Cancer Research and Treatment, 2026
Translational Relevance of the Genomic Landscape of KRASG12D-Mutant Colorectal and Pancreatic Cancers.
Jazieh K et al.
Targeted Oncology, 2026
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.
Hernandez S et al.
Lung Cancer (amsterdam, Netherlands), 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
Prognostic Significance of SOX9 and Its Combination With RAS and TP53 Mutations Following Colorectal Cancer Liver Metastasectomy.
Duan JL et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2025
KRAS and MET Co-Mutation in One Lesion and EGFR Mutation in Another Lesion of Early-Stage Synchronous Multiple Lung Adenocarcinomas: A Case Report.
Ito T et al.
The Tohoku Journal of Experimental Medicine, 2025
Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s).
Wang SA et al.
Haematologica, 2025
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
Hollis RL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Age-Related Multigene Analysis of Colorectal Cancer Using Next-Generation Sequencing.
Kozlowska-Geller M et al.
Cancers, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer.
Safyan RA et al.
Surgical Oncology, 2025
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Voss RK et al.
Leukemia, 2025
Aspyre Lung enables robust variant calling in samples that fail next generation sequencing quality control.
Gray ER et al.
Translational Oncology, 2025
Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.
Liu L et al.
Medcomm, 2025
KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials.
Navarro-Jiménez M et al.
Npj Precision Oncology, 2025
Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer.
Haraguchi E et al.
International Journal of Cancer, 2025
Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities.
Nukaga S et al.
Nature Communications, 2025